Vaccine Trials at an Inflection Point: Operational, Regulatory, and Public Trust Challenges

The vaccine development landscape is under pressure from multiple directions simultaneously. Sponsors that build flexible, standardized, and community-informed trial programs will be better positioned to absorb regulatory change, accelerate timelines, and earn the public trust that ultimately determines whether vaccines reach the populations who need them.

Here are 10 questions addressing the key challenges and opportunities shaping vaccine trials today.

1. Why are Phase III vaccine trials so much more expensive than other late-stage studies, and where does the inefficiency come from?

A typical Phase III drug trial costs roughly $19 million, while a Phase III vaccine trial can range from $60 to $148 million. Vaccine trials typically enroll tens of thousands of healthy participants across global sites within narrow windows, generating enormous data volumes very quickly. A significant share of that cost stems not from the science but from operational inefficiency: sponsors historically design each study from scratch, rebuilding endpoint strategies, eCOA instruments, training flows, and data structures that are largely identical from one vaccine trial to the next.

2. What does a portfolio-level standardization strategy for vaccine trials look like in practice?

A program-level approach means making key decisions once, documenting them, and applying them across all studies in a vaccine portfolio. Instrument selection, recall windows, compliance thresholds, endpoint hierarchy, training flows, and device strategy are defined at the program level rather than reinvented for each protocol.

One top-10 global pharmaceutical company adopted this approach across eight Phase III trials enrolling more than 50,000 participants, achieving 50% reductions in overall eCOA build times and discovering that roughly 80% of data fields were identical across six trials, enabling cross-study harmonization that was previously not feasible.

3. How are AI-enabled platforms changing the economics of vaccine trial builds?

Modern AI-enabled platforms make standardization practical by generating central libraries of reusable components, including questionnaires, diaries, visit schedules, training flows, and translations, that can be assembled, configured, and deployed rapidly.

Previously, building new libraries could take four weeks per trial; with mature libraries and standardized templates, that setup time can shrink to two weeks or less. A well-designed standardized eCOA system can be stood up in two to four weeks and removed from the critical path entirely, converting what has traditionally been a bottleneck into an accelerant for participant engagement and data quality.

4. What were the proposed FDA changes to vaccine approval, and what are their trial design implications?

A 2025 internal FDA memo outlined several significant changes to the vaccine approval process, including higher evidence thresholds requiring more robust safety and clinical value data, stricter authorization standards for vaccines used in pregnant women, a shift requiring pneumonia vaccines to demonstrate actual disease reduction rather than antibody response, and a revised annual influenza vaccine approval framework. The changes also signal potential requirements for larger, longer studies.

Twelve former FDA commissioners publicly challenged these proposals, arguing they would slow development, raise costs, and undermine a regulatory framework designed to ensure vaccines are available when the public needs them most.

5. What is immunobridging and why does its potential curtailment matter operationally?

Immunobridging studies use antibody responses as surrogates for efficacy, allowing regulators to evaluate new strains or formulations without requiring full-scale efficacy trials each time. Former FDA commissioners have emphasized that for rapidly evolving viruses like influenza and SARS-CoV-2, repeating large-scale efficacy trials for every new seasonal strain is not feasible within the time needed to update vaccines. Reducing reliance on immunobridging would require sponsors to conduct more outcome-based efficacy trials, significantly extending development timelines and raising costs for annual vaccine updates.

6. How did the mandate for placebo-controlled trials across all new vaccines affect trial design and recruitment?

Placebo-controlled trials were already the gold standard when no approved alternatives exist, making the premise of a blanket mandate somewhat misleading in context. As Krinx Kong, chief commercial officer at Cognivia, explained in a 2025 interview with Applied Clinical Trials: "The notion that these aren't already in use is misleading, or at least lacks context."

However, mandating placebo use even where active comparators are more appropriate would introduce significant complications: "Ethics boards may push back. If an effective vaccine already exists, withholding it in favor of placebo could be viewed as unethical. This leads to delays, extra review cycles, and potential public concern."

Recruitment would also suffer, as "patients and parents may be reluctant to participate if there's a genuine chance of receiving no active protection."

7. What does vaccine hesitancy research reveal about the most effective strategies for building public trust?

Research from the Tufts Center for the Study of Drug Development examining vaccines that achieved rapid uptake found three primary drivers of vaccine confidence: transparency in clinical evidence and access to information, rebuilding trust damaged by historical inequities in medical research, and diversity in clinical trial populations. Notably, the most effective patient engagement practices were not systematically designed; they emerged from ad hoc decisions and local experimentation. The strategic implication is that these practices, when deliberately institutionalized, can convert vaccine hesitancy from a structural barrier into a manageable operational challenge.

8. How does clinical trial diversity function as a trust-building mechanism specifically for vaccine programs?

When trial populations do not reflect the demographics of those who will ultimately receive a vaccine, both clinicians and patients question whether the results apply to them. This concern is particularly acute for immunocompromised patients and other complex populations that trials have historically excluded.

As the Tufts CSDD research piece concluded, "Participant diversity in clinical trials is not only a scientific necessity but also a trust-building mechanism."

Inclusive trials signal respect for the communities that vaccines aim to protect, and their results carry greater credibility with those same communities during commercialization.

9. What role does behavioral science play in managing participant engagement and dropout risk in vaccine trials?

Behavioral science provides the frameworks needed to understand why participants disengage, how they interpret study expectations, and what motivates continued participation, intelligence that standard operational metrics do not capture.

As Kong described, clinical operations teams must develop what he called behavioral visibility: "It's not enough to track visits, check a box, or lab results. Ops teams must understand the psychological journey of participants, when they're likely to disengage, how they interpret study expectations, and what motivates them to stay."

Predictive tools that monitor adherence, dropout likelihood, and placebo response in real time are increasingly essential for managing the scale and pace of vaccine mega trials.

10. What should clinical operations professionals be prioritizing as vaccine trial policy continues to evolve?

Kong identified three core priorities for clinical operations teams navigating an uncertain regulatory environment.

First, flexibility: "Build trial designs that can adapt to new data, new regs, or even public sentiment, that includes modular protocols and contingency plans for recruitment or site engagement."

Second, behavioral visibility into the participant journey. Third, communication: "Clear, trust building messaging is essential, not just the participants, but also the site staff, to regulators, and the public."

His broader charge to the field was direct: "Be agile, be human centered, and be proactive. Vaccine trials are not just scientific, they're social, and the teams that understand both sides will be the ones who thrive in the next phase of clinical research."